SCHEMBL5300667

SCHEMBL5300667

N[C@@H](CC1=CC(=O)C(=O)C=C1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.44
PKM P14618 2/20 0.44
PTGS1 P23219 2/20 0.44
ALPI P09923 1/20 0.44
XIAP P98170 1/20 0.44
USP2 O75604 3/20 0.41
HSD17B10 Q99714 3/20 0.41
ALOX15 P16050 2/20 0.41
HIF1A Q16665 2/20 0.41
KDM4E B2RXH2 2/20 0.41
RECQL P46063 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP3A4 P08684 2/20 0.41
RGS12 O14924 1/20 0.41
CYP2C9 P11712 1/20 0.41
NFKB1 P19838 1/20 0.41
CASP1 P29466 1/20 0.41
BRCA1 P38398 1/20 0.41
THPO P40225 1/20 0.41
CASP7 P55210 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14441259 1.00 SLC7A5 (0.44) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL1640222 1.00 SLC7A5 (0.44) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL14023473 0.84 SLC7A5 (0.41) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL1076502 0.74 SLC7A5 (0.44) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL3278753 0.74 SLC7A5 (0.41) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL6009735 0.71 USP2 (0.42) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL23996206 0.71 MAPT (0.39) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL29280376 0.70 SLC7A5 (0.46) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL4994581 0.70 SLC7A5 (0.46) SLC7A5PKMPTGS1ALPIXIAP
SCHEMBL25737316 0.69 SLC7A5 (0.37) SLC7A5PKMPTGS1ALPIXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578106-B2 Surfactant adhesive composition TME Therapeutics Co., Ltd. (KR) 2023-02-14 US claimed
CN-115068664-A Bioadhesive compositions comprising mussel adhesive proteins and methods of making the same 浦项工科大学校产学协力团 2022-09-20 CN claimed
US-6335468-B1 CONDENSING N-ACYL AMINO ACID OR SALT THEREOF WITH AMINE AND/OR AMMONIA UNDER DEHYDRATING CONDITIONS IN PRESENCE OF BORON COMPOUND AS CATALYST WITH ALCOHOL COEXISTENT AS AUXILIARY SOLVENT AJINOMOTO CO., INC. (JP) 2002-01-01 US claimed
US-12577287-B2 T cell receptors and methods of use thereof UNIVERSITY HEALTH NETWORK (CA) 2026-03-17 US disclosed
US-20260070944-A1 PEPTIDE PROMOTING TYROSINASE ACTIVITY AND USE THEREOF HYSENSBIO CO., LTD (KR) 2026-03-12 US disclosed
US-20260048001-A1 SKINCARE COMPOSITION CONTAINING CASHEW APPLE EXTRACT R & D GLOBAL CONSULTANTS PVT LTD (IN) 2026-02-19 US disclosed
EP-4582095-A1 PEPTIDE FOR PROMOTING TYROSINASE ACTIVITY AND USE THEREOF Hysensbio Co., Ltd (KR) 2025-07-09 EP disclosed
CN-119866225-A Peptides promoting tyrosinase activity and uses thereof 株式会社海森斯柏奥 2025-04-22 CN disclosed
WO-2025071094-A1 USES OF MERCAPTO FUNCTIONAL COMPOUND HAVING TYROSINASE INHIBITORY ACTIVITY 부산대학교 산학협력단 2025-04-03 WO disclosed
EP-4288102-B1 LAYERED STRUCTURE FOR SPECIFIC CELL CAPTURING UNIV BERLIN FREIE (DE) 2025-04-02 EP disclosed
CN-119326697-B Preparation and application of umbilical cord extract with hair blackening effect by regulating hair follicle melanocyte to produce melanin granule 广州优特佳生物科技发展有限公司 2025-03-28 CN disclosed
US-5210076-A Methods of treating Parkinson's disease using melanin LARGE SCALE BIOLOGY CORPORATION 1993-05-11 US disclosed
EP-0510186-A4 THERAPEUTIC USES OF MELANIN 1993-03-24 EP disclosed
WO-1993002682-A1 METHOD AND COMPOSITIONS FOR REDUCING CRAVING FOR ALCOHOL AND STIMULANTS LABCO PHARMACEUTICALS, INC. (US) 1993-02-18 WO disclosed
EP-0510186-A1 THERAPEUTIC USES OF MELANIN Biosource Technologies, Inc. (US) 1992-10-28 EP disclosed
WO-1992007580-A1 THERAPEUTIC USES OF MELANIN BIOSOURCE GENETICS CORPORATION (US) 1992-05-14 WO disclosed
EP-0434750-A1 PROPHYLAXIS AND TREATMENT OF NERVOUS SYSTEM DISEASES WITH MELANIN. BIOSOURCE GENETICS CORP (US) 1991-07-03 EP disclosed
WO-1990002551-A2 PROPHYLAXIS AND TREATMENT OF NERVOUS SYSTEM DISEASES WITH MELANIN BIOSOURCE GENETICS CORPORATION (US) 1990-03-22 WO disclosed
US-4718994-A HYDROXYLATION LATVIISKY GOSUDARSTVENNY UNIVERSAITET IMENI P. STUCHKI (SU) 1988-01-12 US disclosed
US-4181527-A HYDROPHILIC COLLOID FUJI PHOTO FILM CO., LTD. (JP) 1980-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048001-A1 SKINCARE COMPOSITION CONTAINING CASHEW APPLE EXTRACT EP300, SCD, COL2A1 SLC7A5 1443/4885PKM 3595/4885PTGS1 995/4885
US-20260070944-A1 PEPTIDE PROMOTING TYROSINASE ACTIVITY AND USE THEREOF TYR, ARGLU1, ARG1 SLC7A5 406/4885PKM 1234/4885PTGS1 3205/4885
US-12577287-B2 T cell receptors and methods of use thereof MICA, TAP1, TAP2 SLC7A5 3447/4885PKM 4875/4885PTGS1 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.